{"url_path":"/sec/imux/8-k/2026-09-11/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Principal","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-001219-index.html","accession_number":"0001193805-26-001219","cik":"0001280776","ticker":"IMUX","issuer_name":"IMMUNIC, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-001219-index.html","primary_entity_key":"0001280776","primary_entity_name":"IMMUNIC, INC."},"word_count":110,"has_tables":true,"body_markdown":"**Item 5.02. Departure of Directors or Principal\nOfficers; Election of Directors; Appointment of Principal Officers.**\n\n**Resignation of Director**\n\n \n\nOn September 10, 2026, Dr. Duane Nash resigned\nas a member of the Board of Directors (the “Board”) of Immunic, Inc., a Delaware corporation (the “Company”).\nDr. Nash’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations,\npolicies, or practices. The Board and the Company are deeply grateful for Dr. Nash’s service, dedication, and contributions to the\nCompany.\n\n \n\nIn connection with Dr. Nash’s resignation,\nby resolution of the Board, the size of the Board was reduced from ten members to nine members."}